You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Midostaurin for treating advanced systemic mastocytosis

  • Technology appraisal guidance
  • Reference number: TA728
  • Published:  22 September 2021
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Draft guidance
  4. Invitation to participate
  5. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Equality Impact Assessment (Guidance development) (PDF 153 KB)

    Published:
    22 September 2021

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 223 KB)

    Published:
    19 August 2021
  • Committee papers (PDF 552 KB)

    Published:
    19 August 2021

Draft guidance

  • Draft guidance

  • Appraisal consultation document (online commenting)

  • Appraisal consultation document (PDF version) (PDF 253 KB)

    Published:
    06 November 2020
  • Committee papers (PDF 4.04 MB)

    Published:
    06 November 2020
  • Public committee slides (PDF 814 KB)

    Published:
    06 November 2020

Invitation to participate

  • Final scope (PDF 157 KB)

    Published:
    18 December 2019
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 461 KB)

    Published:
    18 December 2019
  • Equality impact assessment (Scoping) (PDF 123 KB)

    Published:
    18 December 2019
  • Final stakeholder list (PDF 219 KB)

    Published:
    18 December 2019

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft scope post referral (PDF 185 KB)

    Published:
    24 May 2019
  • Draft matrix post referral (PDF 216 KB)

    Published:
    24 May 2019
Back to top